Effect of dehydroepiandrosterone and antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts

Journal of the National Cancer Institute

Volumn 90, Issue 10, 1998, Pages 772-778

  Couillard, Steeve ^a   Labrie, Claude ^a   Bélanger, Alain ^a   Candas, Bernard ^a   Pouliot, Frédéric ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANTIESTROGEN; PRASTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SIZE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MOUSE; NONHUMAN; OVARIECTOMY;

EID: 0032550714     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.10.772     Document Type: Article

References (66)

1. McGuire WL, Carbone PP, Seard ME, Esche GC. Estrogen receptors in human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer EP, editors. Estrogen receptors in human breast cancer. New York: Raven Press, 1975:1-7.
2. Asselin J, Labrie F. Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the rat. J Steroid Biochem 1978;9:1079-82.
3. Osborne CK, Von Hoff DD, Mullins K. Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay. Breast Cancer Res Treat 1985;6:229-35.
4. Davidson NE, Lippman ME. The role of estrogens in growth regulation of breast cancer. Crit Rev Oncog 1989;1:89-111.
5. Dowsett M, Macaulay V, Gledhill J, Ryde C, Nicholls J, Ashworth A, et al. Control of aromatase in breast cancer cells and its importance for tumor growth. J Steroid Biochem Mol Biol 1993;44:605-9.
6. 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 1986;46:4933-7.
7. Tormey DC, Jordan VC. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 1984;4:297-302.
8. Jordan VC. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 1983:3 Suppl:S73-86.
9. Kennedy BJ. Fluxymesterone therapy in treatment of advanced breast cancer. N Engl J Med 1958;259:673-5.
10. Segaloff A, Gordon D, Horwitt BN, Schlosser JV, Murison PJ. Hormonal therapy in cancer of the breast. 1. The effect of testosterone propionate therapy on clinical course and hormonal excretion. Cancer 1951;4:319-23.
11. Fels E. Treatment of breast cancer with testosterone propionate. A preliminary report. J Clin Endocrinol 1944;4:121-5.
12. Cooperative Breast Cancer Group. Testosterone propionate therapy of breast cancer. JAMA 1964;188:1069-72.
13. Gordan GS, Halden A, Horn Y, Fuery JJ, Parsons RJ, Walter RM. Calusterone (7β,17α-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 1973;28:138-46.
14. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Holzel F, Schulz KD. Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Res 1991;51:5722-7.
15. Simard J, Hatton AC, Labrie C, Dauvois S, Zhao HF, Haagensen DE, et al. Inhibitory effects of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. Mol Endocrinol 1989;3:694-702.
16. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F. Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16′α-chloro-3′,17β-dihydroxyestra- 1′,3′,5′-(10′)triene-7′α-yl]undecanamide in human breast cancer ZR-75-1 cells. Cancer Res 1991;51:2797-802.
17. Poulin R, Baker D, Labrie F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 1988;12:213-25.
18. Poulin R, Baker D, Poirier D, Labrie F. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 1989;13: 161-72.
19. Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagace L, et al. Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 1989;125:392-9.
20. Dumont M, Dauvois S, Simard J, Garcia T, Schachter B, Labrie F. Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. J Steroid Biochem 1989;34: 397-402.
21. Simard J, Dauvois S, Haagensen DE, Levesque C, Merand Y, Labrie F. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology 1990; 126:3223-31.
22. Dauvois S, Geng CS, Levesque C, Merand Y, Labrie F. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res 1991;51:3131-5.
23. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 1991;67: 886-91.
24. Wooster R, Mangion J, Eeles R, Smith S, Dowsett M, Averill D, et al. A germline mutation in the androgen receptor in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992;2:132-4.
25. Lobaccaro JM, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J, Lesimple T, et al. Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 1993;2:1799-802.
26. Trams G, Maass H. Specific binding of estradiol and dihydrotestosterone in human mammary cancers. Cancer Res 1977;37:258-61.
27. Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, et al. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 1979;39:1447-54.
28. Miller WR, Telford J, Dixon JM, Hawkins RA. Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol 1985;21:539-42.
29. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer 1984;54:2436-40.
30. Dauvois S, Li SM, Martel C, Labrie F. Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. Breast Cancer Res Treat 1989;14:299-306.
31. Asselin J, Melancon R, Moachon G, Belanger A. Characteristics of binding to estrogen, androgen, progestin, and glucocorticoid receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and their hormonal control. Cancer Res 1980;40:1612-22.
32. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-C118.
33. Labrie C, Simard J, Zhao HF, Belanger A, Pelletier G, Labrie F. Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and andro-stenedione in the rat ventral prostate. Endocrinology 1989;124:2745-54.
34. Labrie C, Belanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 1988;123:1412-7.
35. Labrie C, Flamand M, Belanger A, Labrie F. High bioavailability of dehydroepiandrosterone administered percutaneously in the rat. J Endocrinol 1996;150:S107-18.
36. Labrie F, Simard J, Luu-The V, Belanger A, Pelletier G, Morel Y. et al. The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. In: Hansson V, Levy FO, Tasken K, editors. Signal transduction in testicular cells. Ernst Schering Research Foundation Workshop. Berlin, Heidelberg, and New York: Springer-Verlag, 1996:185-218.
37. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, et al. The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 1997;62:148-58.
38. Labrie F, Belanger A, Simard J, Van Luu-The, Labrie C. DHEA and peripheral androgen and estrogen formation: intracrinology. Ann N Y Acad Sci 1995;774:16-28.
39. Dauvois S, Spinola PG, Labrie F. Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat. Eur J Cancer Clin Oncol 1989;25:891-7.
40. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, et al. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-y1]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. J Med Chem 1997;40:2117-22.
41. Labrie F, Li S, Labrie C, Levesque C, Merand Y. Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res Treat 1995;33:237-44.
42. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994;34:89-95.
43. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:1-15.
44. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:71-85.
45. Saez RA, Osborne CK. Hormonal treatment of advanced breast cancer. In: Kennedy BJ, editor. Current clinical oncology. New York: Alan R. Liss, 1989:163-72.
46. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 1996; 88:1543-9.
47. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
48. Osborne CK, Coronado EB, Allred DC, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans4-hydroxytamoxifen. J Natl Cancer Inst 1991; 83:1477-82.
49. Osborne CK, Coronado EB, Robinson JP. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987;23: 1189-96.
50. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48: 812-5.
51. Gottardis MM, Jiang SY, Jeng MH, Jordan VC. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989;49:4090-3.
52. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-50.
53. Wakeling AE, Bowler J, ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 1992;43:173-7.
54. Wakeling AE. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 1993;25:1-9.
55. Simard J, Labrie C, Belanger A, Gauthier S, Singh SM, Merand Y, et al. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer 1997;73:104-12.
56. Asselin J, Kelly PA, Caron MG, Labrie F. Control of hormone receptor levels and growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactin. Endocrinology 1977;101: 666-71.
57. Tormey DC, Lippman ME, Edwards BK, Cassidy JG. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 1983;98: 139-44.
58. Segaloff A. The use of androgens in the treatment of neoplastic disease. Pharm Ther 1977;C2:33-37.
59. Labrie F, Auclair C, Cusan L, Kelly PA, Pelletier G, Ferland L. Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. Int J Androl Suppl 1978;2:303-18.
60. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997; 82:3498-505.
61. Li S, Yan X, Belanger A, Labrie F. Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat 1993;29:203-17.
62. Quadri SK, Kledzik GS, Meites J. Counteraction by prolactin of androgen-induced inhibition of mammary tumor growth in rats. J Natl Cancer Inst 1974;52:875-8.
63. Young S, Baker RA, Helfestein JE. The effects of androgens on induced mammary tumors in rats. Br J Cancer 1965;19:155-9.
64. Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 1979;39:1129-32.
65. Luo S, Labrie C, Belanger A, Labrie F. Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. Endocrinology 1997;138:3387-94.
66. Sourla A, Martel C, Labrie C, Labrie F. Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology 1998;139:753-64.